Orchid Pharma ne ek damakedar deal sign ki hai! Agle **10 saal** tak company ka antibiotic 'Exblifep' Latin America ke **9** desh mein bikega, jisse **$80 Million** ka business hone ka plan hai.
Deal ka kya scene hai?
Orchid Pharma ne Laboratorio Libra S.A. ke saath 10 saal ka exclusive contract sign kiya hai. Iske tehat, Orchid ka naya antibiotic 'Exblifep' (Cefepime/Enmetazobactam) ab Latin America ke 9 desh mein launch hoga. Orchid iska manufacturer aur supplier bana rahega, matlab production toh India mein hi hoga.
Investors ke liye kyun important hai?
Is deal se Orchid Pharma ne apni global presence badha li hai. US aur Europe ke baad ab company Latin American markets mein bhi apna paisa daal rahi hai. $80 Million (lagbhag ₹670 Crore) ka revenue agle ek decade mein aane ka projection hai, jo long-term mein company ke liye solid earnings visibility deta hai.
Risky kya hai?
Sab kuch plan ke hisaab se ho, iske liye local regulatory approvals milna zaroori hai. Latin America ke in 9 alag-alag desh ke apne rules hain, aur agar wahan se permission milne mein deri hui, toh revenue aane mein time lag sakta hai.
Aage kya track karein?
Sathguru Management Consultants is deal mein advisor the. Ab investors ko bas ye dekhna hai ki kitni jaldi wahan ki authorities se clearance milta hai. Jitni tezi se permissions milengi, utni jaldi ye $80 Million ka pipeline Orchid ke topline mein add hona shuru ho jayega.